AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Butalbital is a barbiturate that works as a central nervous system depressant. It provides pain relief by acting on the brain to decrease the sensation of pain associated with tension headaches and migraines.
Muscle Relaxation: Butalbital has muscle relaxant properties, which can help alleviate the muscle tension often associated with tension headaches.
Combination Formulations: Butalbital is often combined with other medications, such as acetaminophen (paracetamol) and caffeine, in formulations like Fioricet (butalbital/acetaminophen/caffeine) or Fiorinal (butalbital/aspirin/caffeine). These combinations provide additional pain relief and may enhance the effectiveness of butalbital.
Sedation: Butalbital has sedative effects and may cause drowsiness or dizziness, which can impair cognitive and motor skills. It is important for individuals taking butalbital to avoid activities that require mental alertness, such as driving or operating heavy machinery, until they understand how the medication affects them.
Dependency and Tolerance: Prolonged use of butalbital can lead to physical dependence and tolerance, meaning that higher doses are required over time to achieve the same pain-relieving effects. Abrupt discontinuation of butalbital after long-term use may result in withdrawal symptoms, including rebound headaches.
Risk of Overuse: Because butalbital-containing medications can provide relief from headaches, there is a risk of overuse or misuse, which can lead to medication overuse headaches (MOH). MOH is a type of headache that occurs as a result of frequent or excessive use of headache medications.
Drug Interactions: Butalbital may interact with other medications, including certain antidepressants, sedatives, and alcohol, leading to enhanced sedative effects or respiratory depression. It is essential for healthcare providers to review a patient's medication list and medical history before prescribing butalbital.
Liver Toxicity: Some formulations of butalbital contain acetaminophen, which can cause liver toxicity if taken in high doses or in combination with other medications containing acetaminophen. Patients should be cautioned against exceeding the recommended dosage of acetaminophen.
Cardiovascular Effects: Barbiturates like butalbital can have cardiovascular effects, including hypotension (low blood pressure) and bradycardia (slow heart rate), particularly at high doses.
Pregnancy and Lactation: Butalbital is not recommended during pregnancy, especially during the third trimester, due to the risk of neonatal withdrawal syndrome and respiratory depression in newborns. It may also pass into breast milk and affect nursing infants.
Monitoring and Education: Patients taking butalbital-containing medications should be monitored regularly by their healthcare providers to assess the effectiveness of treatment and monitor for signs of medication overuse or dependence. Patients should also be educated about the potential risks and side effects of butalbital and instructed to use the medication as directed.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0 | 0 | |
ADHD | 1 | 1 | |
Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.2 | 0.5 |
Allergic Rhinitis (Hay Fever) | 1.4 | 0 | 0 |
Allergies | 1.6 | 0.8 | 1 |
Allergy to milk products | 1 | 0.5 | 1 |
Alopecia (Hair Loss) | 0.5 | 0.5 | |
Alzheimer's disease | 2.2 | 1.5 | 0.47 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.4 | 0.9 | 0.56 |
Ankylosing spondylitis | 1.8 | 0.9 | 1 |
Anorexia Nervosa | 0.2 | 0.6 | -2 |
Antiphospholipid syndrome (APS) | 1.2 | 1.2 | |
Asthma | 0.4 | 0.8 | -1 |
Atherosclerosis | 0.6 | 0.9 | -0.5 |
Atrial fibrillation | 0.9 | 0.6 | 0.5 |
Autism | 4.9 | 3.1 | 0.58 |
Barrett esophagus cancer | 0.5 | 0.3 | 0.67 |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 0.6 | 0.2 | 2 |
Brain Trauma | 0.2 | 0.2 | 0 |
Carcinoma | 1.2 | 0.7 | 0.71 |
Celiac Disease | 1.5 | 0.9 | 0.67 |
Cerebral Palsy | 1 | 0.2 | 4 |
Chronic Fatigue Syndrome | 1.9 | 2.3 | -0.21 |
Chronic Kidney Disease | 1.3 | 0.3 | 3.33 |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 0.1 | 18 |
Chronic Urticaria (Hives) | 1.6 | 0.7 | 1.29 |
Coagulation / Micro clot triggering bacteria | 1.3 | 0.4 | 2.25 |
Colorectal Cancer | 3.2 | 0.2 | 15 |
Constipation | 0.8 | 0.1 | 7 |
Coronary artery disease | 0.6 | 0.2 | 2 |
COVID-19 | 5 | 3.9 | 0.28 |
Crohn's Disease | 4.5 | 1.7 | 1.65 |
cystic fibrosis | 0.8 | 0.2 | 3 |
deep vein thrombosis | 0.8 | 0.4 | 1 |
Depression | 3.8 | 3.4 | 0.12 |
Dermatomyositis | 0.3 | 0 | 0 |
Eczema | 0.9 | 1.5 | -0.67 |
Endometriosis | 1.6 | 0.2 | 7 |
Eosinophilic Esophagitis | 0.4 | 0.2 | 1 |
Epilepsy | 1.7 | 1.6 | 0.06 |
Fibromyalgia | 1.8 | 0.8 | 1.25 |
Functional constipation / chronic idiopathic constipation | 2.4 | 1.3 | 0.85 |
gallstone disease (gsd) | 1.2 | 0.5 | 1.4 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 0.3 | 3.33 |
Generalized anxiety disorder | 1.6 | 0.5 | 2.2 |
giant cell arteritis | 0.4 | -0.4 | |
Glioblastoma | 0.3 | -0.3 | |
Graves' disease | 0.5 | 0.4 | 0.25 |
Halitosis | 0.7 | 0.3 | 1.33 |
Hashimoto's thyroiditis | 0.9 | 0.1 | 8 |
Hidradenitis Suppurativa | 0.7 | 0.2 | 2.5 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1 | 0.2 | 4 |
hypercholesterolemia (High Cholesterol) | 0.4 | 0.4 | 0 |
hyperglycemia | 0.3 | 0.9 | -2 |
Hyperlipidemia (High Blood Fats) | 0.4 | 0.2 | 1 |
hypersomnia | 0 | 0 | |
hypertension (High Blood Pressure | 1.2 | 1.2 | 0 |
Hypothyroidism | 0 | 0 | |
Hypoxia | 0.5 | 0.5 | |
IgA nephropathy (IgAN) | 1.4 | -1.4 | |
Inflammatory Bowel Disease | 2.9 | 2.2 | 0.32 |
Insomnia | 0.4 | 0.2 | 1 |
Intelligence | 0.7 | 0.7 | |
Intracranial aneurysms | 0.3 | 0.2 | 0.5 |
Irritable Bowel Syndrome | 2.2 | 1.7 | 0.29 |
Liver Cirrhosis | 2.3 | 1.4 | 0.64 |
Long COVID | 3.3 | 1.8 | 0.83 |
Low bone mineral density | 0.1 | -0.1 | |
Lung Cancer | 0.3 | 0.6 | -1 |
ME/CFS with IBS | 0.7 | 0.5 | 0.4 |
ME/CFS without IBS | 1.2 | 0.8 | 0.5 |
Menopause | 0 | 0 | |
Metabolic Syndrome | 4 | 3.5 | 0.14 |
Mood Disorders | 5.5 | 3.4 | 0.62 |
multiple chemical sensitivity [MCS] | 1.2 | 0 | 0 |
Multiple Sclerosis | 2.8 | 2.3 | 0.22 |
Multiple system atrophy (MSA) | 1.3 | 0 | 0 |
Neuropathy (all types) | 0.5 | 0.3 | 0.67 |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.3 | 0.6 | 1.17 |
NonCeliac Gluten Sensitivity | 0 | 0 | |
Obesity | 3.6 | 2.4 | 0.5 |
obsessive-compulsive disorder | 2.6 | 1.5 | 0.73 |
Osteoarthritis | 1.8 | 1.8 | |
Osteoporosis | 0.9 | 0.5 | 0.8 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 1.8 | 1.6 | 0.13 |
Polycystic ovary syndrome | 1.4 | 0.7 | 1 |
Postural orthostatic tachycardia syndrome | 0.4 | 0 | 0 |
Premenstrual dysphoric disorder | 0.2 | 0.2 | 0 |
primary biliary cholangitis | 0.2 | 0.5 | -1.5 |
Psoriasis | 2.6 | 1 | 1.6 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 1.8 | 0.72 |
Rosacea | 0.3 | 0.5 | -0.67 |
Schizophrenia | 2.8 | 0.5 | 4.6 |
Sjögren syndrome | 1.2 | 0.9 | 0.33 |
Sleep Apnea | 0.4 | 0.2 | 1 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 1.2 | |
Stress / posttraumatic stress disorder | 2.1 | 0.8 | 1.63 |
Systemic Lupus Erythematosus | 2.1 | 0.1 | 20 |
Tic Disorder | 0.4 | 0.4 | 0 |
Tourette syndrome | 0.2 | 0.1 | 1 |
Type 1 Diabetes | 1.3 | 1.2 | 0.08 |
Type 2 Diabetes | 4 | 4.1 | -0.02 |
Ulcerative colitis | 1.8 | 2.2 | -0.22 |
Unhealthy Ageing | 3.2 | 0.3 | 9.67 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.